BIONIK Laboratories Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

TECHNOLOGY AND OTHER ASSETS

TECHNOLOGY AND OTHER ASSETS

9 Months Ended

Dec. 31, 2019

4. TECHNOLOGY AND OTHER ASSETS

The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the nine months ended December 31, 2019, and the year ended March 31, 2019:


		Value	Amortization	Value at	Amortization	Value at
	Amortization	Acquired	March 31, 2019	March 31, 2019	December 31, 2019	December 31, 2019
Intangible assets acquired	period (years)	$	$	$	$	$
Patents and exclusive License Agreement	9.74	1,306,031	134,090	911,440	100,566	810,874
Trademark	Indefinite	2,505,907	—	2,505,907	—	2,505,907
Customer relationships	10	1,431,680	143,168	1,010,375	107,377	902,998
Non compete agreement	2	61,366	1,739	—	—	—
Assembled workforce	1	275,720	—	—	—	—
		5,580,704	278,997	4,427,722	207,943	4,219,779

Amortization expense for the technology and other assets was $207,943 and $209,682 for the nine months ended December 31, 2019 and 2018, respectively. Amortization expensed for the technology and other assets was $69,314 and $69,314 for the three months ended December 31, 2019 and 2018, respectively.